药理疗法用于纠正长视
H Fernández Jiménez-Ortiz1, N Toledano Fernández1
1Servicio de Oftalmología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
Archivos de la Sociedad Espanola de Oftalmologia
|April 25, 2024
概括
对长视障碍的新局部治疗方法在改善近视方面表现有前途. 这些新的疗法,包括针孔效应和透镜放松方法,仍处于早期研究阶段,但有可能对视力进行校正.
科学领域:
- 眼科医生 眼科 眼科
- 视光学测量 视光学测量 视光学测量
- 视觉科学科学 视觉科学
背景情况:
- 长视障碍影响全球17亿至20亿人,影响生活质量和生产力.
- 在适应过程中透镜形状变化的精确机制仍然不完全理解.
- 对长视的局部治疗正在出现,有几种正在研究中.
研究的目的:
- 审查前视障碍治疗的新型局部疗法.
- 评估新兴长视障碍治疗的有效性和安全性.
主要方法:
- 进行了主要生物医学数据库的系统搜索.
- 包括15个随机临床试验和12篇符合预定义标准的评论文章.
- 分析了专注于针孔效应和晶状镜片放松策略的研究.
主要成果:
- 确定了两个主要策略:针孔效应 (增加焦点深度) 和晶状透镜放松 (使用副交感模仿剂和透镜氧化中间体).
- 结果通常表明近视敏度的良好改善.
- 研究的随访期被认为是短暂的.
结论:
- 新型局部治疗是一种有希望的,尽管处于早期阶段,但对长视障碍管理的方法.
- 需要进行更多的随访期的进一步研究,以确认疗效和安全性.
- 这些疗法可以为纠正与年龄相关的近视力损失提供一种有价值的新选择.
相关概念视频
Open Angle Glaucoma: Treatment
440
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
440
Focusing of Light in the Eye
2.7K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.7K
Angle Closure Glaucoma: Treatment
485
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
485
Direct-Acting Cholinergic Agonists: Therapeutic Uses
731
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
731
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.3K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
662
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
662


